title: Aim, design and methods of the 'reasons for not intensifying antihypertensive treatment' (RIAT): an international registry in essential hypertension.
abstract: Failure of physicians to adhere to hypertension guidelines may partly account for the failure to achieve blood pressure (BP) goals in clinical practice. The aim of this trial is a comprehensive description of the approach of physicians in the management of high BP among primary care patients. It will primarily assess what are the Reasons for not Intensifying an Antihypertensive Treatment (RIAT), when predefined individual BP goals are not achieved. Open intervention survey was conducted in 17 countries in Latin America, Eastern Europe, Africa and Asia in family practices, government and private clinics. The registry is based on a three-step epidemiological design. Step one shall identify guidelines and recommendations taken as reference in each country for the management of hypertension. Step two will assess the variance between individual targets defined by physicians in their practice compared to guidelines and recommendations. Step three is a prospective registry where physicians collect patient data at baseline; determine individual target BP values. Several follow-up visits are proposed to monitor achievement of these targets. Step three of RIAT aims at providing responses to several key objectives. Recruitment is under way aiming at enrolling 33,000 patients. To identify, what is the BP targeted according to the risk factor profile and what are the reasons for not modifying an antihypertensive treatment when BP goals are not reached, and to analyse the type of antihypertensive drugs prescribed according to compelling indications and to assess the percentage of patients reaching target figures.
authors.affiliation: Department of Nephrology, Fremantle Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. paolo.ferrari@health.wa.gov.au
authors.forename: P
authors.initials: P
authors.lastname: Ferrari
authors.forename: S-K
authors.initials: SK
authors.lastname: Kim
authors.forename: C J
authors.initials: CJ
authors.lastname: Wu
authors.forename: N V
authors.initials: NV
authors.lastname: Pham
authors.forename: F
authors.initials: F
authors.lastname: Ageev
authors.forename: L D
authors.initials: LD
authors.lastname: Hermosillo
authors.forename: R
authors.initials: R
authors.lastname: Esper
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D003430:Cross-Sectional Studies; D019983:Guideline Adherence; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007391:International Cooperation; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000379:methods; D012042:Registries
chemical_list: D000959:Antihypertensive Agents